Medicus Pharma Ltd. (MDCX) News
Follow Medicus Pharma Ltd. (MDCX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Medicus Pharma Reports Third-Quarter 2026 Financial Results
Medicus Pharma reported third-quarter 2026 financial results. The company also highlighted CD228V as its principal development priority and a proposed SPAC business combination at an approximately $135 million valuation
EQUITY | Nov 06, 2026, 09:36 PM UTC
L
Medicus Pharma Announces Proposed SkinJect Business Combination and Financing
Medicus Pharma announced a proposed SkinJect business combination and concurrent financing.
MNA | Nov 04, 2026, 01:31 PM UTC
H
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Applied Digital Corp (NASDAQ: APLD ) rose sharply in pre-market trading after the company posted better-than-expected financial results for the first quarter. Applied Digital reported first-quarter adjusted rev
LIVE | Oct 08, 2026, 08:32 AM UTC
L
Medicus Pharma Ltd. (MDCX) Seeks FDA OK for Seamless Teverelix Phase 2b/3 To Enable Partnering
Medicus Pharma submitted an optimized seamless Phase 2b/3 protocol to the FDA for Teverelix in advanced prostate cancer, aiming to cut planned enrollment to ~600 from ~1,500 and enable partnering, subject to FDA feedback
REGULATION | Sep 29, 2026, 11:33 AM UTC
L
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company’s capital-efficient development strategyPHILADELPHIA, Sept. 29,
REGULATION | Sep 29, 2026, 11:33 AM UTC
H
Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus
Medicus Pharma Ltd. (NASDAQ: MDCX ) on Monday announced it will concentrate all future internally sponsored clinical development for its SkinJect asset exclusively on Gorlin syndrome patients presenting with multiple bas
LIVE | Sep 21, 2026, 11:32 AM UTC
L
MDCX - Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
MDCX - Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
NEWS | Sep 21, 2026, 11:30 AM UTC
L
Dr. Raza Bokhari Discloses Investment at Medicus Pharma Ltd. with 5.3% Stake
Dr. Raza Bokhari, Chief Executive Officer and Executive Chairman of Medicus Pharma Ltd., disclosed a 5.3% stake in the company’s common shares. He filed a Schedule 13D on Sep. 14, 2026, detailing direct holdings, stock o
EQUITY | Sep 14, 2026, 09:00 PM UTC
L
MDCX - Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the L
MDCX - Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
EQUITY | Sep 10, 2026, 11:30 AM UTC
L
MDCX - Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
MDCX - Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
EQUITY | Sep 08, 2026, 11:30 AM UTC
M
Medicus Pharma inks Pfizer CD228V co-development and global license deal
Medicus Pharma entered a co-development and license agreement with Pfizer for CD228V, a worldwide, early clinical-stage CD228-targeting antibody-drug conjugate. The deal grants an exclusive, sublicensable patent license
EQUITY | Sep 03, 2026, 12:04 PM UTC
L
Medicus Pharma reports Q2 2026 results and corporate update
Medicus Pharma (MDCX) reports its second quarter 2026 financial results and provides a corporate update, with no additional figures included in the provided alert.
EARNINGS | Aug 12, 2026, 10:00 PM UTC
M
MDCX Appoints CEO of Antev Limited
MDCX appoints Dr. Faisal Mehmud as CEO
EQUITY | Aug 03, 2026, 11:30 AM UTC
H
UAE Grants Authorization
UAE authorizes phase 2a study
EQUITY | Jul 31, 2026, 11:30 AM UTC
H
MDCX Receives UAE Health Authorization
MDCX gets UAE approval for medicine study
EQUITY | Jul 31, 2026, 11:30 AM UTC
L
Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study
Medicus Pharma announced...
REGULATION | Jul 27, 2026, 01:10 PM UTC
L
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ: CRIS ) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ: HUMA ) shares moved upwards by 5.45% to $0.71. The marke
EQUITY | Jul 01, 2026, 09:05 PM UTC